Brain-penetrant DRP1-FIS1 inhibitor program
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop CNS-penetrant small molecule inhibitors of the DRP1-FIS1 protein-protein interaction to reduce mitochondrial damage downstream of inflammation, with potential applications in neurodegenerative and age-related diseases such as ALS, Huntington's disease, Alzheimer's disease, and other degenerative CNS conditions.
Drug-like small molecule mimetics of the mito-protective peptide P110 targeting the DRP1-FIS1 interaction; brain-penetrant compounds for CNS indications.
Patent application filing planned for 2024 before Case Western studies.
Brain-penetrant DRP1-FIS1 inhibitors
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop CNS-active DRP1-FIS1 protein-protein interaction inhibitors to mitigate mitochondrial damage downstream of inflammation, with potential applications in neurodegenerative and age-related diseases.
Drug-like small molecule mimetics of the mito-protective P110 peptide targeting the DRP1-FIS1 interaction; brain-penetrant CNS compound series.
Patent application filing planned for 2024 before Case Western studies.
Gut and eye restricted DRP1-FIS1 inhibitors
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop low-penetrance DRP1-FIS1 inhibitors for tissue-restricted delivery to gut and eye indications.
Low-penetrance small molecule DRP1-FIS1 inhibitors designed for gut- and eye-restricted delivery.
Patent application filing planned for 2025 just before IND-enabling studies.
Gut- and eye-restricted low-penetrance DRP1-FIS1 inhibitor program
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop low-penetrance DRP1-FIS1 inhibitors for restricted delivery to the gut and eye, targeting localized degenerative or inflammatory indications involving mitochondrial dysfunction.
Low-penetrance small molecule DRP1-FIS1 inhibitors formulated or selected for gut- and eye-restricted delivery.
Patent application filing planned for 2025 before IND-enabling studies.
In silico DRP1-FIS1 inhibitor discovery platform
exploratoryplatform · medium · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Discover drug-like small molecule inhibitors of DRP1-FIS1 and screen compounds at non-traditional protein-protein interaction binding sites.
GPU-accelerated empirical docking to train a diffusion model for compound screening at binding sites poorly represented in standard AI training datasets.
Described as a trade-secret in silico discovery method in the Fission Pharma assessment proposal.
Peripherally restricted DRP1-FIS1 inhibitor program
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop orally available, peripherally restricted DRP1-FIS1 inhibitors for non-CNS peripheral indications involving chronic inflammation, mitochondrial dysfunction, and age-related degenerative disease.
Orally available small molecule DRP1-FIS1 protein-protein interaction inhibitors designed to avoid CNS penetration and act in peripheral tissues.
Patent application filing planned for 2025 before IND-enabling studies.
Peripherally restricted DRP1-FIS1 inhibitors
preclinicaldrug program · high · Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop orally available DRP1-FIS1 inhibitors for peripheral indications involving inflammation-linked mitochondrial dysfunction and degenerative disease.
Orally available but peripherally restricted small molecule DRP1-FIS1 inhibitors derived from the P110 mimetic strategy.
Patent application filing planned for 2025 just before IND-enabling studies.
